Christina joined Ferring in the first half of 2022 and will report directly to Per Falk, the President.

Based in Copenhagen, Christina will be responsible for leading and overseeing the direction, planning and execution of all aspects of our Reproductive Medicine and Maternal Health portfolio, working together in collaboration with all functions, as well as regional and market teams. A core part of her role will be to develop, lead and operationalise the global RMMH strategy to realise the full potential of our Growth Agenda and ensure we build families worldwide.

Prior to joining Ferring, Christina was CEO of Pharmiva, a Sweden-based women’s health company, with a broad portfolio of patented products in vaginal health. She has more than 20 years of experience in management positions in pharmaceutical companies such as Novo Nordisk where she was Clinical, Regulatory and Medical Director, and also Medical Director Nordics at Ferring between 2002 and 2009.

Christina holds a medical degree from the Faculty of Medicine, Lund University in 1988 and is a specialist in Obstetrics and Gynaecology. She also gained a Medical Business Strategy degree at SIMI Copenhagen 2006 and Executive Foundation Lund board degree in 2014. In addition, she furthered her leadership and management education at Harvard Business and IMD Business School.